Stocks Health care EVFM
OTC · Health careEvofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. brought in $18M of revenue over the twelve months to June 30, 2026, up 4.5% from a year earlier. It posted a net loss of $15.3M. In fiscal 2025 capital spending exceeded operating cash flow by $2M. At June 30, 2026 it held $285K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch EVFM in 60 secondsWhat Evofem Biosciences, Inc. does
Evofem Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker EVFM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $20.2M | $391K | $0.00 | -$2M |
| 2024 | $19.4M | -$8.9M | -$0.11 | -$3.9M |
| 2023 | $18.2M | $53M | $0.05 | -$9M |
| 2022 | $16.8M | -$76.7M | -$153.47 | -$70.8M |
| 2021 | $8.2M | -$205.2M | -$2,706.31 | -$149.6M |
| 2020 | $446K | -$142.3M | -$3,631.25 | -$107.1M |
Full financial statements: income, balance sheet and cash flow
Where EVFM ranks in Health care
Dividends
It paid out $200K in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2018 | n/a | $200K | n/a |
Latest SEC filings
What Evofem Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 45% to $2.6M versus the same quarter last year; diluted EPS -$0.08 versus -$0.01.
- July 20, 2026
- July 14, 2026
- May 18, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 6.4% to $899K versus the same quarter last year; diluted EPS -$0.04 versus $0.00.
- April 30, 2026
- April 16, 2026
- March 19, 2026
- March 11, 2026
Questions about EVFM
What does Evofem Biosciences, Inc. do?
Evofem Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker EVFM.
Is Evofem Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $15.3M on revenue of $18M.
How much revenue does Evofem Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Evofem Biosciences, Inc. reported revenue of $18M. That is 4.5% more than a year earlier.
When did Evofem Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.
Similar companies
Compare EVFM with
Follow EVFM
Get an email when Evofem Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow EVFM: get an email when it filesWhere the numbers come from
Financial figures are the values Evofem Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.